GLP-1 Longevity Signals
Beyond weight and glucose
The interesting question for longevity isn't whether GLP-1s help diabetics — that's settled. It's whether the downstream effects (lower inflammation, better lipids, reduced cardiovascular events, smaller visceral fat depots) translate into extra healthspan years for non-diabetic users.
Inflammation markers drop
SELECT and multiple smaller trials show consistent reductions in high-sensitivity CRP (a key inflammation marker and independent predictor of cardiovascular + all-cause mortality) on GLP-1 therapy — typically 20–40% vs placebo at 1 year.
Kidney + liver protection
FLOW (2024) showed semaglutide reduced kidney-outcome events by 24% in people with type 2 diabetes and chronic kidney disease. Separately, tirzepatide is producing the largest MASH (fatty-liver) improvements seen outside bariatric surgery.
So: a longevity drug?
The honest answer is "probably yes for people with metabolic disease, unclear for metabolically healthy adults." No trial has tested GLP-1s in lean healthy volunteers for all-cause mortality. The benefit in obese + diabetic + CKD populations is real; the generalisation to everyone is speculative.
Brain — the emerging Alzheimer's signal
GLP-1 receptors are expressed in the brain (hippocampus, hypothalamus), and observational studies have repeatedly shown 30–60 % lower Alzheimer's incidence in diabetics on GLP-1s vs other glucose-lowering drugs. The randomised confirmation is in flight: the EVOKE + EVOKE+ trials of oral semaglutide in early Alzheimer's (n=3,720, 2 years) read out late 2025 / early 2026. If positive, GLP-1s become the first drug class with proven mortality + cardiovascular + neurodegenerative benefit — a profile no other longevity candidate matches.
Key Takeaway
GLP-1s reduce inflammation, protect kidneys, improve liver health, and cut cardiovascular events. The Alzheimer's RCT readout in 2026 could expand that profile further. For metabolic disease they're genuinely longevity-extending. For otherwise-healthy adults seeking extra years, the evidence is thin — and the trade-offs (next lesson) start to matter more.